Loading...
Loading...
In a report published this morning, Bank of America's analysts resumed coverage on Biogen Idec
BIIB with a Neutral rating and a $182 PT.
Bank of America reported that, “We rate BIIB shares a Neutral as we see limited upside to consensus estimates, and believe current valuation reflects a very successful Tecfidera launch. New pipeline data readouts are not expected until 2014-2015.”
Biogen Idec currently trades at $178.44.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Price TargetAnalyst Ratings
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in